Users Online: 673
Home
About us
Editorial board
Search
Browse articles
Submit article
Ahead of Print
Instructions
Subscribe
Contacts
Special issues
Login
» Articles published in the past year
To view other articles click corresponding year from the navigation links on the side bar.
All
|
Brief Communication
|
Brief Reports
|
Case Report and Literature Review
|
Case Reports
|
Commentary
|
Editorial
|
Erratum
|
Letter to Editor
|
Letters to Editor
|
Meta Analysis
|
Notice of Retraction
|
Original Article
|
Original Articles
|
Research Articles
|
Review Articles
|
Review Report
|
Short Communications
|
Systematic Review
|
Systematic Review and Meta-Analysis
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Show all abstracts
Show selected abstracts
Export selected to
Add to my list
Review Article:
Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: A new approach to treat type 1 diabetes
Shruti Dave
Adv Biomed Res
2014, 3:266 (31 December 2014)
DOI
:10.4103/2277-9175.148247
PMID
:25625105
The pathophysiology of type 1 diabetes mellitus (T1DM) is largely related to an innate defect in the immune system culminating in a loss of self-tolerance and destruction of the insulin-producing β-cells. Currently, there is no definitive cure for T1DM. Insulin injection does not mimic the precise regulation of β-cells on glucose homeostasis, leading long term to the development of complications. Stem cell therapy is a promising approach and specifically mesenchymal stem cells (MSCs) offer a promising possibility that deserves to be explored further. MSCs are multipotent, nonhematopoietic progenitors. They have been explored as an treatment option in tissue regeneration as well as potential of
in vitro
transdifferentiation into insulin-secreting cells. Thus, the major therapeutic goals for T1DM have been achieved in this way. The regenerative capabilities of MSCs have been a driving force to initiate studies testing their therapeutic effectiveness; their immunomodulatory properties have been equally exciting; which would appear capable of disabling immune dysregulation that leads to β-cell destruction in T1DM. Furthermore, MSCs can be cultured under specially defined conditions, their transdifferentiation can be directed toward the β-cell phenotype, and the formation of insulin-producing cells (IPCs) can be targeted. To date, the role of MSCs-derived IPC in T1DM-a unique approach with some positive findings-have been unexplored, but it is still in its very early phase. In this study, a new approach of MSCs-derived IPCs, as a potential therapeutic benefit for T1DM in experimental animal models as well as in humans has been summarized.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Citations (14) ]
[PubMed]
[Sword Plugin for Repository]
Beta
Review Article:
Immunocontraceptives: How far from reality?
Seema Lekhwani, ND Vaswani, Veena Singh Ghalaut, Vijay Shanker, Ragini Singh
Adv Biomed Res
2014, 3:247 (6 December 2014)
DOI
:10.4103/2277-9175.146369
PMID
:25590025
Despite high expectations of safer, effective, economical, longer acting contraceptives, to date, there are no licensed contraceptive vaccines available in the market. Nevertheless, a role for vaccines undoubtedly exists as an aid to birth spacing and as a nonsurgical means of generating sterility. The research concerned in the area so far has been successful on the feline population, with room still for exhaustive studies on humans. The future of contraceptive vaccines holds great promise in terms of comfort, price, efficacy, rare complications, and possibly nonselective action on animal populations as well as on humans. This brief review deals with the basic aspects of immunocontraceptives along with the efforts done so far. There is a need for further research in aspects involving the rate of evolution of contraception resistance based on genetics, resistance phenotypes, or cross generation effects. Gonadotropin-releasing hormone and luteinizing-hormone have not been investigated in humans, as both reported impotency in animals; the follicle-stimulating hormone has been shown to cause oligospermia; zona pellucida has also not been studied in humans as it causes irreversible oophoritis, while the sperm has the potential for success in humans based on the data from immunoreproductive studies. Even as the position of the human chorionic gonadotropin vaccine looks hopeful, research on other possible targets continue with an eventual aim of discovering a vaccine that is more immunogenically effective.
[ABSTRACT]
[HTML Full text]
[PDF]
[Mobile Full text]
[EPub]
[Citations (3) ]
[PubMed]
[Sword Plugin for Repository]
Beta
Feedback
Subscribe
Advanced Search
Month wise articles
Figures next to the month indicate the number of articles in that month
2023
January
[
1
]
2022
December
[
1
]
November
[
1
]
October
[
2
]
July
[
1
]
June
[
2
]
February
[
1
]
2020
October
[
1
]
2019
October
[
1
]
August
[
1
]
March
[
1
]
February
[
1
]
2018
May
[
1
]
February
[
3
]
2017
July
[
1
]
May
[
1
]
April
[
1
]
March
[
1
]
2016
November
[
1
]
August
[
1
]
July
[
1
]
April
[
2
]
March
[
1
]
2015
September
[
1
]
August
[
1
]
July
[
1
]
June
[
1
]
May
[
2
]
February
[
3
]
January
[
1
]
2014
December
[
2
]
June
[
1
]
May
[
1
]
January
[
6
]
2013
November
[
1
]
July
[
1
]
June
[
1
]
2012
August
[
2
]
July
[
1
]
1900
January
[
1
]
Sitemap
|
What's New
Feedback
|
Copyright and Disclaimer
|
Privacy Notice
© Advanced Biomedical Research | Published by Wolters Kluwer -
Medknow
Online since 15 January, 2012